Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Brokerages

Kenvue Inc. (NYSE:KVUE) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $23.00.

Several equities analysts recently commented on KVUE shares. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Canaccord Genuity Group cut their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th.

Kenvue Stock Up 1.2 %

KVUE stock opened at $22.26 on Thursday. The stock has a 50-day simple moving average of $21.28 and a two-hundred day simple moving average of $22.14. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The firm has a market capitalization of $42.68 billion, a PE ratio of 42.00, a PEG ratio of 2.57 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.68%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Institutional Trading of Kenvue

A number of institutional investors have recently made changes to their positions in the stock. Leo Wealth LLC raised its holdings in Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after buying an additional 481 shares during the last quarter. Alerus Financial NA raised its stake in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC raised its stake in shares of Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after acquiring an additional 500 shares during the last quarter. Principle Wealth Partners LLC grew its stake in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares during the last quarter. Finally, Wolff Wiese Magana LLC increased its holdings in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.